Full Press Release Details
Reports New Data Showing its Psoriasis Drug May Offer Efficacy
Similar to Industry Leading Biologics Without Harmful Side Effects
TIKVA, Israel, June 15, 2016 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline
of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced
new mechanism of action data indicating its lead drug candidate, Piclidenoson (CF101) inhibits two inflammatory cytokines, interleukin
17 (IL-17) and interleukin 23 (IL-23) which are known to play a major role in the inflammatory process of psoriasis.
drugs, which are injectable immunomodulators, for the treatment of psoriasis currently on the market and in development, also
work via a similar mechanism of action by inhibiting IL-17 and IL-23. These systemic drugs offer good efficacy, however, as biologics
they can cause serious side effects.
binds to the Gi protein associated A3 adenosine receptor (A3AR), which is over- expressed in psoriasis patients. This binding
action has shown to induce a robust anti-inflammatory effect by inhibiting IL-17 and IL-23 as demonstrated in in-vitro studies.
An orally administered small molecule drug, Piclidenoson, potentially offers safety superior to biologics as shown in clinical
studies in approximately 1,000 people.
findings will be presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network, in Paris,
France on July 7, 2016. The oral presentation titled, "CF101 via A3AR Activation inhibits IL-17 and IL-23" is scheduled
for 10:10 am during the Late Breaking News Session.
believe that the discovery of this new mechanistic pathway of Piclidenoson will position it as a strong drug candidate to treat
psoriasis with potential efficacy similar to biologics on the market today, while potentially offering superior safety as a small
molecule oral drug," stated Can-Fite CEO, Dr. Pnina Fishman.
global psoriasis market is estimated to reach $9 billion by 2018 (Visiongain). Can-Fite recently announced the submission of its
Phase III protocol design to the European Medicines Agency for Piclidenoson in the treatment of psoriasis and expects to commence
Piclidenoson (CF101)
is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic
index demonstrated in Phase II clinical studies. Piclidenoson is currently under development for the treatment of autoimmune inflammatory
diseases including rheumatoid arthritis (completed Phase II) and psoriasis (completed Phase II/III).
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2016 for two indications, rheumatoid
arthritis and psoriasis. The rheumatoid arthritis Phase III protocol has recently been agreed with EMA. Can-Fite's liver cancer
drug CF102 is in Phase II trials for patients with liver cancer and is slated to enter Phase II for the treatment of non-alcoholic
steatohepatitis (NASH). CF102 has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration. CF102 has also shown proof of concept
to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has
shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to
the FDA and a Phase I trial. These drugs have an excellent safety profile with experience in over 1,000 patients in clinical
studies to date. For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other
things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition,
from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does
not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future
events or otherwise.